The United Nations Office at Geneva
Multimedia Newsroom
COVID-19: UN health agency issues conditional advice against using remdesivir
Patients with COVID-19 should not be given the antiviral drug remdesivir “regardless of disease severity”, the UN World Health Organization (WHO) said on Friday.
Nonetheless, describing its recommendation as “conditional”, as opposed to “strong”, WHO stressed that data from a global trial on the efficacy of remdesivir was inconclusive, and that further trials should continue into its use for more vulnerable patients.
“We recommend a conditional recommendation – I want to highlight that - against the use of remdesivir in hospitalised patients with COVID-19 regardless of disease severity,” said Dr Janet Diaz, Head of Clinical Care at WHO, during a virtual press conference in Geneva.
According to data from the WHO-led Solidarity trial which was then examined by a panel of international experts behind the recommendation, “possibly remdesivir can lead to 29 fewer deaths per 1,000 patients or up to 11 more deaths per 1000 patients”, Dr Diaz said. “So you can see that …the confidence interval are relatively large…there was no evidence that there was any important effect on mortality, on the need for mechanical ventilation or the time to clinical improvement.”
But this did “not prove” that the antiviral “had no benefit at all”, Dr Diaz insisted. “There could still be potential small benefit, maybe in a health sub-group which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
The WHO official explained that this might be “severe patients versus critical patients” or whether the antiviral is used “early versus late”.
Dr Bram Rochwerg, who was among the experts advising WHO, noted that there would likely be regional “variations” in the use of remdesivir.
While a minority of people will still choose to use it, the majority would not, based on the available data, he said.
“There may be groups (who might benefit) and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit,” he said. “We were very explicit that we do believe that these studies need to continue (and) Solidarity is continuing.”
Although the remdesivir development mirrors similar attempts to use other antivirals against the new coronavirus, Dr Diaz said there was no reason to lose hope in the fight against COVID-19.
“I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
Latest data from WHO indicates that eight in 10 people infected with COVID report mild symptoms, Dr Diaz said.
“Since the beginning (of the pandemic)…about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
Nonetheless, there are reports of more “persistent longer-term symptoms”, Dr Diaz noted. “So even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We recommend a conditional recommendation - so I want to highlight that, it’s a conditional recommendation - against the use of remdesivir in hospitalized patients - with COVID-19, regardless of disease severity.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Possibly remdesivir can lead to 29 fewer deaths par 1,000 patients or up to 11 more deaths per 1,000 patients so you can see that this is, the confidence interval is a little bit large.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “It was not clear that, there was no evidence, that there was any important effect on mortality, on the need for mechanic ventilation or the time to clinical improvement.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “This did not prove that remdesivir does not have a benefit at all and that’s why it is a conditional recommendation, there can still be potential small benefit, maybe in a health sub-group, which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “You know, is there a sub-group that may benefit more – such as severe patients versus critical patients. Is there a timing in disease that may benefit more - such as early versus late - and those are all considerations that are in the guidelines.”
- SOUNDBITE (English) — Dr Bram Rochwerg, practising ITU clinician and expert adviser for WHO-led Solidarity Trial: “There may be groups and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit. And as she said, we were very explicit that we do believe that these studies need to continue, Solidarity is continuing, so.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to, I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Since the beginning, is that about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We do know that even patients with mild disease may have persistent longer-term symptoms. And that has been now described; so even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
Similar Stories
1
1
1
Edited News | UNHCR , WHO , UNMAS
Urgent help is needed to halt a deadly cholera outbreak that is sweeping across Sudan, UN agencies said on Friday, while warning that communities continue to be terrorized by parties to the conflict even as they flee violence.
2
2
1
2
Press Conferences , Edited News , Images | UNEP
Negotiations got under way at UN Geneva on Tuesday to agree on a legally binding treaty to curb plastic pollution, with delegates from nearly 180 countries attending.
1
1
1
Edited News | OCHA , UNICEF
Gaza: Hundreds of trucks per day of free aid needed “for months”, in addition to commercial supplies - OCHA
Despite the tactical pauses Israel introduced last week to allow some safe passage for humanitarian convoys, the amount of aid that has entered Gaza remains by far insufficient for the starving population, and UN trucks continue to face impediments on their way to delivering aid.
1
1
1
Edited News | UN WOMEN
Aid agencies echoed wider warnings of growing signs of widespread starvation in Gaza on Tuesday, as UN-partnered international food security experts released their most dire assessment yet of the situation in the wartorn enclave.
1
1
1
Edited News | IOM , UNDP , UNHCR
Sudan: urgent help needed as more than 1.3 million war-displaced people begin to return home
As conflict rages on across parts of Sudan, pockets of relative safety have emerged in the past four month, spurring more than one million internally displaced Sudanese to make their way home, says the International Organization for Migration (IOM). A further 320,000 cross-border refugees have come back to Sudan since last year, mainly from Egypt and South Sudan, to assess the current situation before deciding to return to their country for good.
1
1
1
Edited News | UNRWA , WHO
Gaza: SOS messages describe people fainting from hunger; UN health worker detained
Worrying alerts from United Nations staff in Gaza who have been fainting from hunger and exhaustion over the past 48 hours have increased fears for people’s survival in the devastated enclave, UN humanitarians said on Tuesday.
1
1
1
Edited News | UNHCR , UNOG
Over 11.6 million refugees risk losing aid access due to funding cuts, says UNHCR
Approximately one in three refugees and other vulnerable individuals normally supported by the UN refugee agency (UNHCR) are expected to lose out from funding cuts, it said on Friday.
1
1
1
Edited News | OHCHR
Ravina Shamdasani, Spokesperson for the Office of the UN High Commissioner for Human Rights, made the following announcement on the Office’s opening of a new mission in Bangladesh.
1
1
1
Edited News | OHCHR
“The surge in the number of Afghans forced or compelled to return to Afghanistan this year is creating a multi-layered human rights crisis requiring the urgent attention of the international community,” UN Human Rights spokesperson Ravina Shamdasani said on Friday.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk on Friday called for accountability and justice for the killings and other gross human rights violations and abuses in the southern city of Suweida.
1
1
1
Edited News | OHCHR , UNHCR
Syria: hundreds killed in Sweida, ‘widespread’ violations as civilians flee for their lives
Amid violent clashes in southern Syria’s Sweida governorate, a picture of grave human rights abuses and rising humanitarian needs is emerging by the hour, the UN said on Friday.
1
1
Edited News | OHCHR , UNOG
At the bi-weekly press briefing in Geneva the UN Human Rights Spokesperson Liz Throssell made the following statement on the latest number of civilian casualties in Ukraine.